HEALTH

Vaxcyte shares surged after its experimental VAX-31 pneumococcal vaccine met the main goals of a late-stage trial, though regulatory approval and commercial manufacturing remain years away.

ImmunityBio shares rose more than 11% as investors weighed accelerating Anktiva sales, international expansion, regulatory milestones and the FDA's planned January 2027 decision on broader use.

Iovance Biotherapeutics shares rose more than 20% after the company raised its 2026 revenue forecast, citing accelerating demand for its melanoma therapy Amtagvi.

Kodiak Sciences shares surged 143% after the biotech said Zenkuda and tabirafusp-ted met key Phase 3 goals in wet age-related macular degeneration, though full data and regulatory review remain pending.

CareDx shares rose nearly 8% after BTIG maintained its Buy rating and raised its price target to $74, while investors weighed clinical progress, acquisitions and valuation risks.

Twist Bioscience shares rose 10.27% to $174.78, extending a near-493% annual rally after an Eli Lilly partnership, higher revenue guidance and improving operating trends.

Lakefront Biotherapeutics shares rose 7.36% on Euronext Amsterdam as investors continued to assess the former Galapagos NV's rebrand, strategic changes and financial outlook.

Viking Therapeutics shares rose nearly 30% after maintenance-trial results showed patients retained most of their weight loss on less frequent dosing of experimental drug VK2735.

Braveheart Bio shares rose 5.5% after the company began its pivotal Phase 3 trial of BHB-1893 and reported financial results supporting development of two late-stage programmes.

Attovia Therapeutics shares rose 8.36% to $24.63, extending a run of sharp, unexplained moves as investors await clinical updates from the biotechnology company's pipeline.

Alamar Biosciences shares jumped 15.9% to $37.10, nearing their 52-week high as investors responded to analyst upgrades, partnerships and progress in precision proteomics.

Telix Pharmaceuticals shares rose 11.26% after the FDA approved Pixclara, its brain cancer imaging drug, extending a rally driven by the regulatory milestone.

GSK shares climbed after the company reported encouraging clinical trial results for two lung cancer treatments, strengthening its oncology strategy despite mixed analyst views on the stock.

BARCELONA, Spain — People with asthma who started semaglutide, the drug sold as Ozempic and Wegovy, had nearly 40% fewer attacks than similar patients on older diabetes pills, researchers told a European lung meeting this week.

Daraxonrasib, a newly approved drug for pancreatic cancer, shows potential in shrinking tumors in lung cancer patients, targeting a broad range of RAS mutations with a novel mechanism.

Regis Healthcare shares fell 29% despite reporting record financial results, highlighting ongoing concerns over aged care funding uncertainty affecting Australia's largest aged care operators.

Johnson & Johnson's stock reached a record high following FDA approval of its drug Imaavy and a positive sales forecast, despite ongoing legal challenges and market pressures.

Pfizer's stock rises to a 52-week high following a drug pricing deal with the Trump administration, strong earnings, and a legal settlement resolution, marking a significant recovery for the company.

Ramsay Health Care's shares rose over 14% as investors anticipate its full-year earnings and a European business spinoff, signalling renewed confidence in the company's turnaround strategy.

AbCellera Biologics' stock surged after positive Phase 2 trial results for its menopause drug, ABCL635. The company's market value increased significantly, driven by investor enthusiasm and analyst upgrades.

Disney will end health insurance for employees' spouses with access to other coverage in 2027, citing rising costs, despite record profits. The change affects over 200,000 employees.

Recent studies reveal GLP-1 weight loss drugs like Ozempic and Wegovy offer unexpected benefits, including reduced alcohol cravings and arthritis relief, but also pose risks like muscle loss and gastrointestinal issues.

Moderna's shares surged 90% after a successful Phase 3 trial of its mRNA cancer vaccine for melanoma, developed with Merck, showing significant benefits over existing treatments.

Ticketmaster's new identity verification process aims to prevent bots from buying tickets, but raises privacy concerns among users due to the collection of biometric and personal data.

Amylyx Pharmaceuticals' shares soared 48% after announcing positive Phase 3 trial results for avexitide, a drug targeting post-bariatric hypoglycemia, marking a significant milestone for the biotech company.

Mesoblast shares surged 8.82% on the ASX after a volatile week, recovering losses from a securities filing that unsettled investors. The company's revenue growth and clinical progress remain key focus areas.

Alamar Biosciences reported an 82% revenue growth in Q2 2026, issued its first full-year revenue guidance, and launched new products, boosting its stock by 17.58% since its IPO in April.

AbCellera Biologics' stock surged over 30% after its menopause drug, ABCL635, showed significant efficacy in a Phase 2 trial, reducing hot flash frequency and severity, with no serious adverse events.

Iovance Biotherapeutics' shares rose 34% after reporting record second-quarter revenue and receiving FDA Fast Track Designation for its cancer therapy, Amtagvi, signalling strong growth and investor confidence.